VEGFA and cancer: Targeted inhibition of different oncogenic signaling pathways has yielded promising therapeutic benefit in some patients with cancer, including KIT inhibitors (imatinib), BRAF inhibitors (vemurafenib and dabrafenib), VEGF inhibitors, PARP inhibitors, and EGFR (erlotinib)- and HER2 (lapatinib)-directed therapies.